The latest flu season facts and autoimmune arthritis – A “must” readIf you have not had your flu shot yet, read this “hot off the press” news from the American College of Rheumatology Annual Scientific Meeting presented yesterday in San Diego, California:Temporary Methotrexate Discontinuation for 2 Weeks Improves Immunogenicity of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial.People with rheumatoid arthritis who stop taking methotrexate treatment for just two weeks after they have a seasonal flu shot can improve the vaccine’s efficacy without increasing rheumatoid arthritis disease activity.
State of Arthritis Medications: Some old, some new, all important
The reliable, quick reference arthritis medications guide you need to assist you and your health care team with your therapy conversations.
The JointHealth™ Medications Guide gives you information on the most commonly prescribed medications for inflammatory types of arthritis and osteoarthritis. Medication information for the following diseases is included in this year’s guide: rheumatoid arthritis, ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, systemic lupus erythematosus, vasculitis, osteoarthritis, and osteoporosis.
In this JointHealth™ insight, you will also find:
- An explanation of the naming changes in the different categories of
- Insight into the patient-physician therapy conversation by Cheryl Koehn, Founder and President of Arthritis Consumer Experts
- Updated disease information for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis, and lupus
- The latest research on methotrexate and the consumption of alcoholic beverages
Arthritis Consumer Experts is excited to unveil a new look and proud to announce a new name for our JointHealth™ newsletter: JointHealth™ insight.
For 17 years, our mission has been to bring valuable, unbiased, evidence-based and consumer-focused information and education programs in both official languages to people living with arthritis. This hasn’t changed. What is changing is the look and feel of our newsletter through a redesign and name change. Our new look reflects what our readers have told us in multiple surveys. Many of you have commented on how treatment options and reimbursement access are evolving and changing quickly. Readers living with inflammatory arthritis and osteoarthritis have also told us about unmet information needs, particularly regarding working with their rheumatologist, disease management and the importance of learning from other consumers’ personal experiences. Continue reading